Insider Buying: Cosmos Health (NASDAQ:COSM) CEO Buys $222,072.75 in Stock

Cosmos Health Inc. (NASDAQ:COSM) CEO Grigorios Siokas purchased 493,495 shares of the business’s stock in a transaction on Wednesday, January 14th. The shares were acquired at an average cost of $0.45 per share, for a total transaction of $222,072.75. Following the completion of the transaction, the chief executive officer directly owned 7,738,474 shares in the company, valued at approximately $3,482,313.30. This represents a 6.81% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Grigorios Siokas also recently made the following trade(s):

• On Monday, January 12th, Grigorios Siokas acquired 113,185 shares of Cosmos Health stock. The stock was bought at an average price of $0.50 per share, with a total value of $56,592.50.
• On Thursday, January 8th, Grigorios Siokas bought 156,190 shares of Cosmos Health stock. The stock was bought at an average cost of $0.52 per share, for a total transaction of $81,218.80.
• On Wednesday, January 7th, Grigorios Siokas bought 124,880 shares of Cosmos Health stock. The shares were bought at an average price of $0.52 per share, for a total transaction of $64,937.60.
• On Tuesday, January 6th, Grigorios Siokas purchased 133,953 shares of Cosmos Health stock. The stock was bought at an average price of $0.54 per share, with a total value of $72,334.62.
• On Friday, December 19th, Grigorios Siokas purchased 88,314 shares of Cosmos Health stock. The shares were bought at an average cost of $0.49 per share, for a total transaction of $43,273.86.
• On Monday, December 15th, Grigorios Siokas acquired 168,472 shares of Cosmos Health stock. The shares were bought at an average price of $0.42 per share, for a total transaction of $70,758.24.
• On Friday, November 28th, Grigorios Siokas acquired 76,360 shares of Cosmos Health stock. The stock was bought at an average cost of $0.64 per share, with a total value of $48,870.40.
• On Tuesday, November 25th, Grigorios Siokas bought 55,732 shares of Cosmos Health stock. The stock was purchased at an average cost of $0.63 per share, with a total value of $35,111.16.
• On Friday, November 21st, Grigorios Siokas bought 56,080 shares of Cosmos Health stock. The shares were purchased at an average price of $0.68 per share, for a total transaction of $38,134.40.
• On Thursday, November 20th, Grigorios Siokas purchased 51,315 shares of Cosmos Health stock. The shares were purchased at an average cost of $0.62 per share, for a total transaction of $31,815.30.

Cosmos Health Stock Performance

Shares of COSM stock opened at $0.52 on Friday. The company has a fifty day moving average price of $0.55 and a two-hundred day moving average price of $0.73. Cosmos Health Inc. has a one year low of $0.28 and a one year high of $1.32. The stock has a market cap of $19.63 million, a P/E ratio of -0.70 and a beta of 5.37. The company has a debt-to-equity ratio of 0.25, a current ratio of 0.99 and a quick ratio of 0.84.

Cosmos Health (NASDAQ:COSM) last released its quarterly earnings data on Friday, November 14th. The company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.16). Cosmos Health had a negative return on equity of 33.19% and a negative net margin of 31.01%.The firm had revenue of $17.11 million for the quarter, compared to analyst estimates of $16.40 million. As a group, equities analysts predict that Cosmos Health Inc. will post -0.78 EPS for the current year.

Cosmos Health News Roundup

Here are the key news stories impacting Cosmos Health this week:

• Positive Sentiment: Significant CEO insider accumulation — CEO Grigorios Siokas disclosed a purchase of 493,495 shares at ~$0.45 on Jan. 14 (raising his stake ~6.8%), adding to multiple buys earlier in January; heavy insider buying signals management confidence and likely underpins short‑term buying interest. Read More.
• Positive Sentiment: Zacks Small‑Cap initiation with optimistic projections — Zacks initiated coverage and models revenue growth (~$130M+ by 2027) and a path to positive EPS by FY2027, which is a near‑term sentiment booster for a micro‑cap stock. Read More.
• Positive Sentiment: Growing institutional interest — filings show funds (e.g., Citadel) increased positions recently, which can improve liquidity and provide steady demand for shares. Read More.
• Neutral Sentiment: Zacks’ forward EPS trajectory is model‑driven — the research projects FY2027 EPS ~ $0.07, but these estimates depend on execution (U.S. expansion, AI R&D, product rollouts) and are not confirmed results. Read More.
• Negative Sentiment: Recent fundamentals remain weak — the company missed on EPS in its last report, posts negative margins and ROE, and consensus still forecasts a full‑year loss (~‑$0.78), keeping near‑term earnings risk elevated. Read More.
• Negative Sentiment: Valuation and disclosure caveats — Zacks used a high discount rate in its model and the report was paid/sponsored, which raises impartiality and model‑assumption risk for investors. Read More.
• Negative Sentiment: High volatility and small‑cap risk — COSM’s tiny market cap and high beta make the share price prone to sharp swings; broker coverage is limited and consensus ratings skew toward Sell, increasing trading risk. Read More.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Cosmos Health stock. Citadel Advisors LLC raised its position in shares of Cosmos Health Inc. (NASDAQ:COSM) by 133.1% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 225,507 shares of the company’s stock after purchasing an additional 128,776 shares during the period. Citadel Advisors LLC owned approximately 0.65% of Cosmos Health worth $250,000 at the end of the most recent reporting period. 12.61% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on COSM shares. Wall Street Zen raised Cosmos Health to a “hold” rating in a report on Saturday, September 20th. Weiss Ratings restated a “sell (d-)” rating on shares of Cosmos Health in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has a consensus rating of “Sell”.

Cosmos Health Company Profile

Cosmos Health Inc manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, Cayman Islands, and Cyprus. It offers medicines, OTC medicines, nutraceutical products, vitamins, minerals and dietary, health care products, medical devices, baby products, and others under the Sky Premium Life and Mediterranation brand names. The company serves wholesale distributors and other healthcare providers, such as clinics, government agencies, independent retail and specialty pharmacies and independent specialty distributors.